Synthetic Biologics Enters License Agreement with Cedars-Sinai Medical Center to Develop New Treatments for IBS, Obesity, Diabetes

Synthetic Biologics Enters License Agreement with Cedars-Sinai Medical Center to Develop New Treatments for IBS, Obesity, Diabetes

Synthetic Biologics (NYSE MKT: SYN) announced today that it entered into worldwide license and option agreements with Cedars-Sinai Medical Center (“Cedars-Sinai”) for the development of new treatment approaches to target non-bacterial intestinal microorganism life forms known as archaea that are associated with intestinal methane production and chronic diseases such as irritable bowel syndrome (IBS), obesity and type 2 diabetes, through its newly formed subsidiary, Synthetic Biomics, Inc.

See full press release

Posted-In: News Guidance Contracts Management Global


Benzinga – Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals


Uncategorized

Leave a Reply

Your email address will not be published. Required fields are marked *